Page last updated: 2024-11-04

salicylsalicylic acid and Hyperglycemia

salicylsalicylic acid has been researched along with Hyperglycemia in 3 studies

salicylsalicylic acid: structure
salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.

Hyperglycemia: Abnormally high BLOOD GLUCOSE level.

Research Excerpts

Excerpt	Relevance	Reference
"These data show that salsalate can reduce sevoflurane-induced hyperglycemia in mice."	8.02	Sevoflurane-induced hyperglycemia is attenuated by salsalate in obese insulin-resistant mice. ( Brown, RE; Desjardins, EM; Smith, BK; Steinberg, GR, 2021)
"These data show that salsalate can reduce sevoflurane-induced hyperglycemia in mice."	4.02	Sevoflurane-induced hyperglycemia is attenuated by salsalate in obese insulin-resistant mice. ( Brown, RE; Desjardins, EM; Smith, BK; Steinberg, GR, 2021)
"Chronic subacute inflammation is implicated in the pathogenesis of insulin resistance and type 2 diabetes."	2.73	Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. ( Aldhahi, W; Cai, D; Goldfine, AB; Lee, J; Shoelson, SE; Silver, R; Tatro, E, 2008)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Desjardins, EM	1
Smith, BK	1
Steinberg, GR	1
Brown, RE	1
Shrestha, S	1
Bhattarai, BR	1
Kafle, B	1
Lee, KH	1
Cho, H	1
Goldfine, AB	1
Silver, R	1
Aldhahi, W	1
Cai, D	1
Tatro, E	1
Lee, J	1
Shoelson, SE	1

Clinical Trials (10)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Study of Inhibition of Inflammation in the Dysmetabolic Syndrome of Obesity[NCT00258115]	Phase 2	20 participants (Actual)	Interventional	2003-12-31	Completed
Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study)[NCT01775865]	Phase 2	59 participants (Actual)	Interventional	2012-09-30	Completed
Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)[NCT00624923]	Phase 2/Phase 3	340 participants (Actual)	Interventional	2008-09-30	Completed
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate[NCT00799643]	Phase 2/Phase 3	638 participants (Actual)	Interventional	2008-11-30	Completed
Effect of Salicylate on Glucose Metabolism in Insulin Resistance States[NCT00258128]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2000-01-31	Completed
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate[NCT00392678]	Phase 2/Phase 3	277 participants (Actual)	Interventional	2006-10-31	Completed
Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach[NCT01398943]		60 participants (Actual)	Interventional	2010-09-30	Completed
Acetylsalicylic Acid Administered in Patients With Type 2 Diabetes Mellitus and Its Effect on the Antioxidant Enzyme System[NCT03341117]	Phase 3	21 participants (Actual)	Interventional	2014-12-02	Completed
Using Salsalate to Target Adipocyte Macrophage Infiltration and Reverse Metabolic Disease Risk in Obese Hispanic Young Adults[NCT02130804]	Phase 1	30 participants (Actual)	Interventional	2011-07-31	Completed
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study[NCT03222206]	Phase 4	34 participants (Actual)	Interventional	2017-11-08	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Brachial Artery Flow-mediated Dilation (FMD)

Endothelial function (NCT01775865)
Timeframe: Change from baseline brachial artery FMD at 4 weeks

Intervention	Percent dilation (Mean)
	Baseline	4 Weeks
Placebo	3.57	2.50
Salsalate	3.49	4.60
Young Control Group	5.88	NA

Carotid-femoral Pulse Wave Velocity (CFPWV)

Aortic stiffness (NCT01775865)
Timeframe: Change in CFPWV from baseline at 4 weeks

Intervention	cm/sec (Mean)
	Baseline	4 weeks
Placebo	785.1	740.01
Salsalate	831.3	839.6
Young Control Group	538.0	NA

Change in Cholesterol

secondary (NCT00624923)
Timeframe: Baseline to 30 mo

Intervention	mg/dL (Mean)
1- Active Pharmacologic	5.1
2- Placebo	2.0

Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT

Secondary outcome, change in liver inflammation associated with NASH: ALT (NCT00624923)
Timeframe: baseline to 30 mo

Intervention	U/L (Mean)
1- Active Pharmacologic	-1.1
2- Placebo	-0.6

Change in Inflammation Marker: CRP

Secondary outcome of change in inflammation marker CRP (NCT00624923)
Timeframe: baseline to 30 mo

Intervention	mg/L (Mean)
1- Active Pharmacologic	-0.1
2- Placebo	-0.1

Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months

(NCT00624923)
Timeframe: Baseline to 30 months

Intervention	mm^3 (Mean)
1- Active Pharmacologic	0
2-Placebo	0

Change From Baseline in Fasting Glucose Over Time.

(NCT00799643)
Timeframe: 48 weeks from baseline

Intervention	mg/dl (Mean)
Placebo	2.0
Salsalate	-13.1

The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.

HbA1c (%, percentage of HbA1c) change from baseline. (NCT00799643)
Timeframe: 48 weeks from baseline

Intervention	HbA1c units are % (Mean)
Placebo	-0.04
Salsalate	-0.33

Adiponectin

(NCT00258128)
Timeframe: 4 weeks

Intervention	mg/ml (Mean)
Salsalate	22.7
Placebo	10.6

Glucose

fasting glucose (NCT00258128)
Timeframe: 4 weeks

Intervention	mmol/L (Mean)
Placebo	7.1
Salsalate	6.4

Change From Baseline and Trends in Fasting Glucose Over Time

(NCT00392678)
Timeframe: 14 week

Intervention	mg/dl (Mean)
Placebo	13
Salsalate 3.0 g/d	-19
Salsalate 3.5 g/d	-14
Salsalate 4.0 g/d	-15

Change From Baseline in 14-week Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in insulin from Baseline to Week 14 in data table below. (NCT00392678)
Timeframe: Baseline, week 14

Intervention	pmol/l (Median)
Placebo	-3.0
Salsalate 3.0 g/d	15
Salsalate 3.5 g/d	7.6
Salsalate 4.0 g/d	27

Change in HbA1c

Change from baseline to either 14 or 26 weeks, or last HbA1c measurement prior to rescue therapy (NCT00392678)
Timeframe: 14 week

Intervention	% HbA1c (Mean)
Placebo	0
Salsalate 3.0 g/d	-0.4
Salsalate 3.5 g/d	-0.3
Salsalate 4.0 g/d	-0.5

Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1

The primary outcome for the TINSAL-T2D study is change in HbA1c level from baseline to week 14 (stage 1) in the intent-to-treat (ITT) population with last observation carried forward. (NCT00392678)
Timeframe: 14 week

Intervention	% (units of HbA1c) (Mean)
3.0 g/d	-0.36
3.5 g/d	-0.34
4.0 g/d	-0.49
Placebo	-0.01

Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in C-peptide from Baseline to Week 14 is in the data table below (NCT00392678)
Timeframe: Baseline, week 14

Intervention	C-peptide in nmol/l (Mean)
Placebo	0.10
Salsalate 3.0 g/d	-0.07
Salsalate 3.5 g/d	-0.03
Salsalate 4.0 g/d	0.03

Safety and Tolerability

See adverse event module for details. Safety and tolerability of salsalate compared to placebo as assessed by adverse events. (NCT00392678)
Timeframe: 14 weeks

Intervention	participants (Number)
Salsalate 3.0 g/d	17
Salsalate 3.5 g/d	16
Salsalate 4.0 g/d	16
Placebo	14

Change in Lipids

"Change in lipids (low-density lipoprotein cholesterol [LDL-C], non-high-density lipoprotein cholesterol [non-HDL-C], triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL C], TC/HDL-C ratio, and LDL-C/HDL-C ratio)~LDL-C/HDL-C ratio not calculated" (NCT00392678)
Timeframe: 14 week

,,,

Intervention	mg/dl (Mean)
	Cholesterol	HDL	LDL	TG	Total to HDL ratio
Placebo	0	0	0	15	0
Salsalate 3.0 g/d	8	3	15	-34	0.1
Salsalate 3.5 g/d	-1	1	3	-22	-0.1
Salsalate 4.0 g/d	6	2	8	-16	0.2

Flow-Mediated Dilation (FMD)

Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post FMD was taken approximately 110 min after baseline

Intervention	percentage of change in FMD (Mean)
	Placebo	AOC Treatment
All Controls	6.7	6.9
All COPD Patients	3.1	4.7

Pulse Wave Velocity

A measure of vascular stiffness at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post PWV was taken approximately 90 min after baseline

Intervention	m/sec (Mean)
	Placebo	AOC Treatment
All Controls	11	10
All COPD Patients	14	11

Trials

1 trial available for salicylsalicylic acid and Hyperglycemia

Article	Year
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008

Other Studies

2 other studies available for salicylsalicylic acid and Hyperglycemia

Article	Year
Sevoflurane-induced hyperglycemia is attenuated by salsalate in obese insulin-resistant mice. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2021, Volume: 68, Issue:7 Topics: Animals; Blood Glucose; Glucose; Hyperglycemia; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Obese	2021
Derivatives of 1,4-bis(3-hydroxycarbonyl-4-hydroxyl)styrylbenzene as PTP1B inhibitors with hypoglycemic activity. Bioorganic & medicinal chemistry, 2008, Sep-15, Volume: 16, Issue:18 Topics: Animals; Anti-Obesity Agents; Blood Glucose; Disease Models, Animal; Fasting; Glucose Tolerance Test	2008